Valuation: Fusion Antibodies plc

Market Cap 7.51M 10.06M 9.01M 8.29M 14.04M 955M 14.3M 98.83M 39.67M 502M 37.76M 36.95M 1.58B P/E 2027 *
-4.62x
P/E 2028 * -
Enterprise Value 7.51M 10.06M 9.01M 8.29M 14.04M 955M 14.3M 98.83M 39.67M 502M 37.76M 36.95M 1.58B EV / Sales 2027 *
5.78x
EV / Sales 2028 * -
Free-Float
87.63%
Yield 2027 *
-
Yield 2028 * -
1 day-5.51%
1 week+4.35%
Current month-47.83%
1 month-50.00%
3 months-41.46%
6 months-57.89%
Current year-57.14%
1 week 5
Extreme 5
6.7
1 month 4.7
Extreme 4.7
12
Current year 4.7
Extreme 4.7
17
1 year 4.7
Extreme 4.7
20
3 years 2.8
Extreme 2.8
21
5 years 2.8
Extreme 2.8
134
10 years 2.8
Extreme 2.8
250
Manager TitleAgeSince
Chief Executive Officer 59 15/08/2022
Director of Finance/CFO 52 24/08/2023
Chief Operating Officer - 01/10/2023
Director TitleAgeSince
Director/Board Member 71 01/01/2007
Chairman 68 01/09/2011
Director/Board Member 50 01/09/2011
Date Insider Type Main position Quantity % Market Cap. Importance
17/02/26 Others

Chairman

200,000 0.1760%
27/01/26 Free

Chief Technology Officer

125,282 0.1102%
27/01/26 Free

Chief Executive Officer

183,438 0.1614%
Change 5-day change 1-year change 3-year change Capi.($)
-5.51%+4.35%-52.94%+17.07% 10.63M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average -0.48%+5.29%+42.15%+149.25% 39.27B
Weighted average by Cap. +0.01%+3.64%+49.44%+162.23%

Financials

2027 *2028 *
Net sales 1.3M 1.74M 1.56M 1.43M 2.43M 165M 2.48M 17.11M 6.87M 86.99M 6.54M 6.4M 274M -
Net income -1.64M -2.19M -1.97M -1.81M -3.06M -208M -3.12M -21.56M -8.65M -110M -8.24M -8.06M -346M -
Net Debt - -
Projected Income Statement - Annual - Fusion Antibodies plc
Logo Fusion Antibodies plc
Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The Company offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development. It offers a range of services including antibody discovery/generation, development, characterization, optimization, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanization using Fusion's proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for downstream use by the customer to produce material for clinical trials. Its Integrated Therapeutic Antibody Services (ITA) offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Employees
27
Date Price Change Volume
30/10/26 GBX 6.000 -5.51% 391,825
29/10/26 GBX 6.350 +1.60% 963,694
28/10/26 GBX 6.250 +13.64% 971,763
27/10/26 GBX 5.500 0.00% 300,088
26/10/26 GBX 5.500 0.00% 48,074

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fusion Antibodies plc